Condition: T-Cell Leukemia/Lymphoma, Adult · Sponsor: Istituto Oncologico Veneto IRCCS
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels. Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined. The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.
This description comes directly from the study's public registry record.
Michele Gottardi, MD · +39 0423732336 · michele.gottardi@iov.veneto.it
GianLuca De Salvo, MD · +390498215704 · gianluca.desalvo@iov.veneto.it
Always discuss trial participation with your own doctor first.
| Istituto Nazionale Tumori Fondazione G.Pascale | Naples, Italy | Recruiting |
| Istituto Oncologico Veneto | Padova, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06600568